scispace - formally typeset
Journal ArticleDOI

Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996

TLDR
There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.
Abstract
Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...

read more

Citations
More filters
Journal ArticleDOI

Role of Maintenance Immunosuppressive Regimen in Kidney Transplant Outcome

TL;DR: Analysis of kidney transplant outcome using three common immunosuppressive protocols suggests that a PCM regimen is associated with lower risk for graft failure compared with a PTM regimen and with lowerrisk for graftFailure and recipient deathCompared with a PCA regimen.
Journal ArticleDOI

Immune Monitoring in Kidney Transplant Recipients Revisited

TL;DR: The discovery and clinical implementation of several new immunosuppressant agents along with a variety of advances in clinical care have made a significant impact on the outcome of organ transplantation.
Journal ArticleDOI

Iodine-125 prostate seed brachytherapy in renal transplant recipients: an analysis of oncological outcomes and toxicity profile.

TL;DR: 125I prostate seed brachytherapy is associated with high rates of biochemical control and minimal toxicity to the renal graft in RTRs, and should be considered as an alternative to surgery in managing R TRs with localized prostate cancer.
Journal ArticleDOI

Predicting long-term kidney graft survival: Can new trials be performed?

TL;DR: Twelve-month Cr level is an accurate surrogate for long-term outcome in graft loss and the use of a combined endpoint (graft loss and 12- month Cr level) allows trials to be performed without exorbitant numbers.
Journal ArticleDOI

Anal Dysplasia in Kidney Transplant Recipients

TL;DR: A large sample is required to more accurately quantify risk factors for dysplasia and progression to cancer, and one time anal cytology sampling was not predictive of histologic findings.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI

Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal ArticleDOI

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI

Risk factors for chronic rejection in renal allograft recipients.

TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Related Papers (5)